Emmanuel Sunday Omirin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Emmanuel Sunday Omirin has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Ehisdiame Favour Okoh
Eureka Laboratory, Anatomy Department, Babcock University, Ogun State, Nigeria
2 shared publicationsEzekiel Abiola Olugbogi
Eureka Laboratory, Anatomy Department, Babcock University, Ogun State, Nigeria
2 shared publications- Ezekiel Abiola Olugbogi
Babcock University
2 shared publications - Oluwafemi Ojo Agosile
Adekunle Ajasin University
2 shared publications Precious Oluwasanmi Aribisala
Anatomy Department Eureka Laboratory Babcock University Ogun State Nigeria
2 shared publicationsSamuel Oluwaseun Boboye
Eureka Laboratory, Anatomy Department, Babcock University, Ogun State, Nigeria
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1) , 90
Hibiscus sabdariffa ameliorates tramadol-induced neurotoxicity via antioxidant, anti-inflammatory, anti-apoptotic, and neurotransmission-regulating mechanisms
Introduction: The misuse and abuse of tramadol, a synthetic opioid analgesic, has become a major public health concern in Africa. Although effective for managing moderate to severe pain, tramadol exposure has been associated with central nervous system toxicity. Hibiscus sabdariffa , commonly consumed as “Zobo,” contains bioactive substances with potent antioxidant and anti-inflammatory properties. Therefore, this study investigated the neuroprotective potential of aqueous H. sabdariffa extract (HSE) against tramadol-induced neurotoxicity in male Swiss mice. Methodology: Fifty adult male mice were randomly assigned into five groups namely control (normal saline), tramadol (50 mg/kg), and three treatment groups receiving tramadol intraperitoneally plus HSE given through oral route at 50, 100, and 200 mg/kg for 21 days. Neurobehavioral tests assessed motor coordination, cognition, anxiety, and depressive-like behaviors. Brain regions, including the hippocampus, prefrontal cortex, and cerebellum, were analyzed for malondialdehyde, reduced glutathione, catalase, superoxide dismutase, glutathione-S-transferase, nitrite levels, acetylcholinesterase activity, and pro-inflammatory cytokines, including interleukin-6, and tumour necrosis factor-alpha. Histological analysis was performed using Nissl staining, while RT-PCR quantified neurotransmission- and apoptosis-related genes, including GAD2, TH, TP53, BAX, and BCL-2. Molecular docking evaluated interactions of H. sabdariffa phytocompounds with target proteins. Results: Tramadol exposure significantly impaired behavior, increased oxidative stress and inflammation, depleted antioxidant defenses, and induced neuronal damage with altered gene expression. H. sabdariffa extract treatment dose-dependently mitigated these alterations, preserved neuronal architecture, and modulated apoptosis-related genes. Docking computation identified Quercetin-3-O-rutinoside, Baicalin, and Delphinidin-3-O-sambubioside as hit compounds with strong binding affinity to target proteins of the genes evaluated in the RT-PCR. Conclusion: Hibiscus sabdariffa aqueous extract activity suggests robust neuroprotective effects against tramadol-induced neurotoxicity through coordinated antioxidant, anti-inflammatory, anti-apoptotic, and neuromodulatory mechanisms. These findings position H. sabdariffa extract as a promising, accessible therapeutic candidate for managing opioid-induced CNS damage.
- 28 August 2026
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 50 (1) , 90
Open AccessHibiscus sabdariffa ameliorates tramadol-induced neurotoxicity via antioxidant, anti-inflammatory, anti-apoptotic, and neurotransmission-regulating mechanisms
Introduction: The misuse and abuse of tramadol, a synthetic opioid analgesic, has become a major public health concern in Africa. Although effective for managing moderate to severe pain, tramadol exposure has been associated with central nervous system toxicity. Hibiscus sabdariffa , commonly consumed as “Zobo,” contains bioactive substances with potent antioxidant and anti-inflammatory properties. Therefore, this study investigated the neuroprotective potential of aqueous H. sabdariffa extract (HSE) against tramadol-induced neurotoxicity in male Swiss mice. Methodology: Fifty adult male mice were randomly assigned into five groups namely control (normal saline), tramadol (50 mg/kg), and three treatment groups receiving tramadol intraperitoneally plus HSE given through oral route at 50, 100, and 200 mg/kg for 21 days. Neurobehavioral tests assessed motor coordination, cognition, anxiety, and depressive-like behaviors. Brain regions, including the hippocampus, prefrontal cortex, and cerebellum, were analyzed for malondialdehyde, reduced glutathione, catalase, superoxide dismutase, glutathione-S-transferase, nitrite levels, acetylcholinesterase activity, and pro-inflammatory cytokines, including interleukin-6, and tumour necrosis factor-alpha. Histological analysis was performed using Nissl staining, while RT-PCR quantified neurotransmission- and apoptosis-related genes, including GAD2, TH, TP53, BAX, and BCL-2. Molecular docking evaluated interactions of H. sabdariffa phytocompounds with target proteins. Results: Tramadol exposure significantly impaired behavior, increased oxidative stress and inflammation, depleted antioxidant defenses, and induced neuronal damage with altered gene expression. H. sabdariffa extract treatment dose-dependently mitigated these alterations, preserved neuronal architecture, and modulated apoptosis-related genes. Docking computation identified Quercetin-3-O-rutinoside, Baicalin, and Delphinidin-3-O-sambubioside as hit compounds with strong binding affinity to target proteins of the genes evaluated in the RT-PCR. Conclusion: Hibiscus sabdariffa aqueous extract activity suggests robust neuroprotective effects against tramadol-induced neurotoxicity through coordinated antioxidant, anti-inflammatory, anti-apoptotic, and neuromodulatory mechanisms. These findings position H. sabdariffa extract as a promising, accessible therapeutic candidate for managing opioid-induced CNS damage.
- Open Access
- 23 December 2024
- Published by IPS Intelligentsia Publishing Services
- Vol. 3 (1) , 36-44
Identification of Antagonists of Pro-Survival Bcl-2 from Morus alba in Human Malignancies
The target of most cancer chemotherapeutic agents is to drive cancer cells toward death, necessitating the need to find a fine balance between anti-apoptotic and pro-apoptotic proteins in maintaining cellular homeostasis. Any shift favoring the pro-apoptotic proteins is needed to drive cellular death in cancer chemotherapy. Therefore, this study uses molecular docking, ADMET predictions, and molecular dynamics simulations for the identification of potent inhibitors of anti-apoptotic Bcl-2 from Morus alba (mulberry). Our molecular docking study discovered that quercetin-3-(6- malonylglucoside) (-10.912kcal/mol) and epigallocatechin gallate (-9.750kcal/mol) recorded excellent binding affinity against human Bcl-2, better than popular standard drugs, venetoclax (-9.468(kcal/mol) and navitoclax (-9.058kcal/mol). Interactions profile summary clearly showed that hydrophobic interactions at TRP141, VAL145, and TYR105 were consistently maintained by the ligands, and all the compounds, except venetoclax, consistently maintained the hydrogen bonding at TYR105. MD simulation analysis showed that the protein and ligand RMSD for the quercetin-3-(6-malonylglucoside)-Bcl-2 complex fell within permissible range, suggesting the ligand is capable of functioning as apposite antagonists of Bcl-2. Epigallocatechin gallate also bind excellently with the target, and both ligands showed favorable ADMET parameters. Summarily, this study identifies two compounds of mulberry as potential drug candidate in the management of known human malignancies, and therefore suggest the compounds should further be assessed through in vitro and in vivo approaches to validate the reports documented here.
- 23 December 2024
- Published by IPS Intelligentsia Publishing Services
- Vol. 3 (1) , 36-44
Open AccessIdentification of Antagonists of Pro-Survival Bcl-2 from Morus alba in Human Malignancies
The target of most cancer chemotherapeutic agents is to drive cancer cells toward death, necessitating the need to find a fine balance between anti-apoptotic and pro-apoptotic proteins in maintaining cellular homeostasis. Any shift favoring the pro-apoptotic proteins is needed to drive cellular death in cancer chemotherapy. Therefore, this study uses molecular docking, ADMET predictions, and molecular dynamics simulations for the identification of potent inhibitors of anti-apoptotic Bcl-2 from Morus alba (mulberry). Our molecular docking study discovered that quercetin-3-(6- malonylglucoside) (-10.912kcal/mol) and epigallocatechin gallate (-9.750kcal/mol) recorded excellent binding affinity against human Bcl-2, better than popular standard drugs, venetoclax (-9.468(kcal/mol) and navitoclax (-9.058kcal/mol). Interactions profile summary clearly showed that hydrophobic interactions at TRP141, VAL145, and TYR105 were consistently maintained by the ligands, and all the compounds, except venetoclax, consistently maintained the hydrogen bonding at TYR105. MD simulation analysis showed that the protein and ligand RMSD for the quercetin-3-(6-malonylglucoside)-Bcl-2 complex fell within permissible range, suggesting the ligand is capable of functioning as apposite antagonists of Bcl-2. Epigallocatechin gallate also bind excellently with the target, and both ligands showed favorable ADMET parameters. Summarily, this study identifies two compounds of mulberry as potential drug candidate in the management of known human malignancies, and therefore suggest the compounds should further be assessed through in vitro and in vivo approaches to validate the reports documented here.
- 19 November 2024
- Published by Springer Nature in In Silico Pharmacology
- Vol. 12 (2) , 107
QSAR, molecular docking, MD simulations, and ADMET screening identify potential Heliotropium indicum leads against key targets in benign prostatic hyperplasia
Steroid 5α-reductase (5αR) converts testosterone into dihydrotestosterone (DHT), a potent androgen driving prostate cell proliferation via the androgen receptor (AR). Both 5αR and AR play crucial roles in androgen-mediated disorders, making them key therapeutic targets in drug development. Current treatments target these enzymes individually and often cause significant side effects, highlighting the need for safer alternatives. Through in silico screening, 13 pyrrolizidine alkaloids of Heliotropium indicum (HI) were assessed for their inhibitory potential against 5αR and AR. Using machine learning, six alkaloids showed promising pIC50 values. The accuracy of the models was assessed using key statistical parameters, including the score, correlation coefficient for training sets (R2), correlation coefficient for test sets (Q2), standard deviation (SD), and root mean square error (RMSE). For 5αR, the results were 0.763 (R2), 0.781 (Q2), 0.748 (score), 0.362 (SD), and 0.832 (RMSE), while for AR, the values were 0.817 (R2), 0.783 (Q2), 0.713 (score), 0.427 (SD), and 0.782 (RMSE), indicating reliability. Europine-N-oxide (-10.27 kcal/mol) and Heliotridine-N-oxide (-9.72 kcal/mol) displayed stronger 5αR binding than Finasteride, while Heliotrine (-10.09 kcal/mol) and Europine-N-oxide (-8.76 kcal/mol) outperformed Enzalutamide in AR binding. Key hydrogen bonds and MD simulations confirmed stable interactions. Pharmacokinetic screening revealed favorable drug-like profiles, including good solubility and absorption with minimal CYP enzyme inhibition. These findings suggest that HI alkaloids are promising multi-target inhibitors for BPH treatment, warranting further in vivo validation and optimization.
- 19 November 2024
- Published by Springer Nature in In Silico Pharmacology
- Vol. 12 (2) , 107
QSAR, molecular docking, MD simulations, and ADMET screening identify potential Heliotropium indicum leads against key targets in benign prostatic hyperplasia
Steroid 5α-reductase (5αR) converts testosterone into dihydrotestosterone (DHT), a potent androgen driving prostate cell proliferation via the androgen receptor (AR). Both 5αR and AR play crucial roles in androgen-mediated disorders, making them key therapeutic targets in drug development. Current treatments target these enzymes individually and often cause significant side effects, highlighting the need for safer alternatives. Through in silico screening, 13 pyrrolizidine alkaloids of Heliotropium indicum (HI) were assessed for their inhibitory potential against 5αR and AR. Using machine learning, six alkaloids showed promising pIC50 values. The accuracy of the models was assessed using key statistical parameters, including the score, correlation coefficient for training sets (R2), correlation coefficient for test sets (Q2), standard deviation (SD), and root mean square error (RMSE). For 5αR, the results were 0.763 (R2), 0.781 (Q2), 0.748 (score), 0.362 (SD), and 0.832 (RMSE), while for AR, the values were 0.817 (R2), 0.783 (Q2), 0.713 (score), 0.427 (SD), and 0.782 (RMSE), indicating reliability. Europine-N-oxide (-10.27 kcal/mol) and Heliotridine-N-oxide (-9.72 kcal/mol) displayed stronger 5αR binding than Finasteride, while Heliotrine (-10.09 kcal/mol) and Europine-N-oxide (-8.76 kcal/mol) outperformed Enzalutamide in AR binding. Key hydrogen bonds and MD simulations confirmed stable interactions. Pharmacokinetic screening revealed favorable drug-like profiles, including good solubility and absorption with minimal CYP enzyme inhibition. These findings suggest that HI alkaloids are promising multi-target inhibitors for BPH treatment, warranting further in vivo validation and optimization.
- Open Access
Molecular Dynamics Simulations on Quercetin-3-(6-Malonylglucoside) From Morus Alba Shows Optimal Inhibition of Bcl-2 with Favorable Anti-Tumor Activities
The target of most cancer chemotherapeutic agents is to drive cancer cells toward death. A fine balance between anti-apoptotic and pro-apoptotic proteins is needed to maintain cellular homeostasis. Any shift favoring the pro-apoptotic ones is needed to drive cellular death in cancer chemotherapy. However, anti-apoptotic proteins such as Bcl-2 and Bcl-xL bind with pro-apoptotic proteins to hinder apoptosis mechanisms. Overexpression of these anti-apoptotic proteins lead to several cancers by preventing apoptosis. In this study, molecular docking, ADMET predictions, and molecular dynamics simulations were performed for the identification of potent inhibitors of anti-apoptotic Bcl-2 with compounds of Morus alba. Our study discovered that Quercetin-3-(6-Malonylglucoside) and Epigallocatechin gallate recorded excellent binding affinity with Bcl-2. Therefore, we conclude that compounds of Morus alba should be subjected to further experimental studies ( in vitro and in vivo) in order to confirm the findings that they could be used as better options in cancer chemotherapy.
Open AccessMolecular Dynamics Simulations on Quercetin-3-(6-Malonylglucoside) From Morus Alba Shows Optimal Inhibition of Bcl-2 with Favorable Anti-Tumor Activities
The target of most cancer chemotherapeutic agents is to drive cancer cells toward death. A fine balance between anti-apoptotic and pro-apoptotic proteins is needed to maintain cellular homeostasis. Any shift favoring the pro-apoptotic ones is needed to drive cellular death in cancer chemotherapy. However, anti-apoptotic proteins such as Bcl-2 and Bcl-xL bind with pro-apoptotic proteins to hinder apoptosis mechanisms. Overexpression of these anti-apoptotic proteins lead to several cancers by preventing apoptosis. In this study, molecular docking, ADMET predictions, and molecular dynamics simulations were performed for the identification of potent inhibitors of anti-apoptotic Bcl-2 with compounds of Morus alba. Our study discovered that Quercetin-3-(6-Malonylglucoside) and Epigallocatechin gallate recorded excellent binding affinity with Bcl-2. Therefore, we conclude that compounds of Morus alba should be subjected to further experimental studies ( in vitro and in vivo) in order to confirm the findings that they could be used as better options in cancer chemotherapy.
- Open Access
- 22 June 2023
- Published by Springer Nature in Research Square
The inhibitory effect of common food spices bioactive compounds against KRAS G12C and KRAS G12D: an in-silico approach
More than 19 percent of all human cancer cases globally express mutant RAS proteins, which are the most frequently altered oncogenic proteins. Targeting cancer cells becomes difficult because these oncogenic proteins and cancer cells that are driven by Ras mutation show very aggressive traits. KRAS is the most expressed among the three isoforms of Ras mutation, which usually occur at position 12. KRAS G12C and KRAS G12D are common types of KRAS that have been proven difficult to target for many years. In recent times, many studies started to show that a lot of food spices possess strong anticancer properties that can target many cancer cells. Therefore, computational methods to access the anticancer properties of some selected compounds that are present in common food spices against KRAS G12C and KRAS G12D in their inactive GDP-bound state. These compounds were molecularly docked with standard drugs after their ADMET screening revealed their druglikeness. Chlorogenic acid and Rosmarinic acid displayed better binding affinity to the targets than all other drugs studied in this research. Molecular dynamics simulation was used to verify this compound's stability. Therefore, after extensive experimental effort, it is most likely that Rosmarinic acid would be effective as a KRAS G12C medicine.
- 22 June 2023
- Published by Springer Nature in Research Square
Open AccessThe inhibitory effect of common food spices bioactive compounds against KRAS G12C and KRAS G12D: an in-silico approach
More than 19 percent of all human cancer cases globally express mutant RAS proteins, which are the most frequently altered oncogenic proteins. Targeting cancer cells becomes difficult because these oncogenic proteins and cancer cells that are driven by Ras mutation show very aggressive traits. KRAS is the most expressed among the three isoforms of Ras mutation, which usually occur at position 12. KRAS G12C and KRAS G12D are common types of KRAS that have been proven difficult to target for many years. In recent times, many studies started to show that a lot of food spices possess strong anticancer properties that can target many cancer cells. Therefore, computational methods to access the anticancer properties of some selected compounds that are present in common food spices against KRAS G12C and KRAS G12D in their inactive GDP-bound state. These compounds were molecularly docked with standard drugs after their ADMET screening revealed their druglikeness. Chlorogenic acid and Rosmarinic acid displayed better binding affinity to the targets than all other drugs studied in this research. Molecular dynamics simulation was used to verify this compound's stability. Therefore, after extensive experimental effort, it is most likely that Rosmarinic acid would be effective as a KRAS G12C medicine.